EPO and myelodysplastic syndrome: EPO responders and non-responders’ MDS patients appeared to have different percentage of cells that express EPOR as well as different expression levels of EPO. Therefore, these preliminary results suggest that EPO/EPOR axis could be used as a predictive biomarker of therapy response.